Liver transplant rejection is a natural reaction of the body’s defense system to a new organ, but with proper care and medication, most people can manage this challenge and live healthy lives with their transplanted liver.

When a New Liver Faces the Body’s Defense

After someone receives a liver transplant, their journey toward recovery includes learning to live with a new organ that the body initially sees as foreign. The main goal of treatment after a liver transplant is to prevent the body’s immune system from attacking the new liver while maintaining the patient’s overall health and quality of life. Managing rejection depends on many factors, including how soon after transplant the rejection occurs, the severity of the immune response, and each patient’s individual characteristics. There are treatments that have been approved by medical societies and used successfully for years, and there is also ongoing research into new approaches that may offer even better outcomes in the future.^[3]

The immune system’s job is to protect the body from anything it recognizes as dangerous or foreign, such as bacteria, viruses, and other threats. When a transplanted liver arrives in the body, the immune system identifies it as something that doesn’t belong because the antigens—proteins on the surface of cells—are different from the recipient’s own cells. This triggers the immune system to launch an attack, which is what we call rejection. Without treatment, this immune response could damage or destroy the new liver, leading to organ failure.^[2][5]

Interestingly, the liver behaves somewhat differently from other transplanted organs like kidneys or hearts. While rejection can and does occur, acute rejection of a liver transplant usually does not lead to long-term graft failure if it is caught and treated promptly. In fact, most episodes of acute rejection respond well to treatment with steroid medications. Chronic rejection, which develops slowly over months or years, is less common in liver transplants compared to other organ transplants, though it presents more serious challenges when it does occur.^[3]

Standard Treatment: Medications to Prevent and Manage Rejection

The cornerstone of preventing liver transplant rejection is a group of medications called immunosuppressants. These medicines work by reducing the activity of the immune system so it cannot attack the transplanted liver. Every person who receives a liver transplant will need to take immunosuppressants for the rest of their life. The transplant team carefully selects and adjusts these medications to find the right balance—enough suppression to prevent rejection, but not so much that the patient becomes dangerously vulnerable to infections.^[2][6]

The most commonly used immunosuppressive medications include tacrolimus, cyclosporine, and prednisone. Tacrolimus is currently the most frequently prescribed drug as the foundation of immunosuppression in liver transplant recipients. It works by blocking certain signals in immune cells called T-cells, preventing them from activating and attacking the new liver. Cyclosporine functions in a similar way and may be used instead of tacrolimus in certain patients. Prednisone belongs to a class of drugs called corticosteroids and helps reduce inflammation and suppress immune responses.^[2][3]

The doses of these medications are not fixed—they need to be adjusted frequently, especially in the first months after transplant. The transplant team monitors blood levels of the drugs through regular testing to ensure the patient is getting the right amount. If drug levels are too low, rejection becomes more likely; if they are too high, the risk of serious side effects increases. White blood cell counts are also checked regularly because they provide important information about how well the immune system is being controlled.^[2]

The period of highest risk for rejection is typically the first three to six months after transplant. During this time, higher doses of immunosuppressants are usually needed, and patients are monitored very closely with frequent blood tests and clinic visits. As time passes and the body adjusts, medication doses may be gradually reduced, though they can never be stopped completely.^[5][15]

When acute rejection occurs despite preventive medication, the standard treatment is a course of high-dose corticosteroids, usually given intravenously (through a vein) in what’s called a “steroid bolus.” This approach is effective in most cases, with the majority of acute rejection episodes improving after this treatment. Acute rejection occurs in about 15 to 25 percent of liver transplant recipients who are taking tacrolimus-based immunosuppression. Fortunately, steroid-resistant rejection—when the rejection doesn’t improve with steroids—is uncommon.^[3][9]

Chronic rejection is a more difficult problem. This type of rejection develops gradually over months or years after transplant and causes damage to the small blood vessels and bile ducts inside the liver. Unlike acute rejection, chronic rejection does not always respond to increased immunosuppression. Some patients improve when their immunosuppressive medications are adjusted or intensified, but a significant number do not respond to treatment. When chronic rejection progresses despite treatment, it can lead to irreversible loss of liver function, which may require a second transplant or could lead to death.^[3][12]

Side Effects and Risks of Immunosuppressive Treatment

While immunosuppressants are essential for protecting the transplanted liver, they come with important side effects that patients need to understand and manage. Because these medications weaken the immune system, the most significant risk is increased susceptibility to infections. Patients are more vulnerable to all types of infections—bacterial, viral, and fungal—especially in the first few months after transplant when medication doses are highest. Common infections include oral yeast infections (thrush), herpes virus reactivation, and respiratory infections.^[2][15]

Other potential side effects of long-term immunosuppression include kidney damage, high blood pressure, diabetes, elevated cholesterol and triglyceride levels, weight gain, and weakening of the bones (osteoporosis). Long-term use of these medications also increases the risk of developing certain cancers, particularly skin cancers. For this reason, transplant recipients need to be vigilant about sun protection and should have regular skin examinations.^[15]

Additional medications are often prescribed to prevent infections or manage side effects. For example, patients may receive antifungal medications to prevent yeast infections and antiviral drugs to prevent herpes or other viral infections. Blood pressure medications, cholesterol-lowering drugs, and medications to protect bone health may also be needed. The transplant team works closely with each patient to monitor for side effects and adjust treatments as needed.^[2]

Diagnosing Rejection: How Doctors Know What’s Happening

Detecting rejection early is crucial for successful treatment. The challenge is that rejection can sometimes occur without causing any symptoms that the patient notices. This is called subclinical acute rejection or “silent” rejection—the rejection process has begun, but the patient feels completely normal. This is why regular monitoring with blood tests is so important after a liver transplant.^[4][10]

Blood tests that measure liver function are usually the first sign that something might be wrong. These tests check levels of liver enzymes and other substances in the blood that indicate how well the liver is working. Abnormal results may be the earliest indicator of rejection, even before any symptoms appear.^[15]

When rejection does cause symptoms, patients may experience fever (especially above 100°F), yellowing of the skin and the whites of the eyes (jaundice), dark-colored urine, light or pale-colored stools, pain or tenderness in the abdomen (particularly in the upper right area where the liver is located), persistent fatigue or weakness, nausea and vomiting, loss of appetite or unexplained weight loss, swelling of the abdomen or legs, itching, headaches, irritability, or even confusion and changes in mental status. Any of these symptoms should be reported to the transplant team immediately.^[2][4][10]

The definitive way to diagnose rejection is through a liver biopsy. During this procedure, a small sample of liver tissue is removed and examined under a microscope to look for signs of immune system damage. The biopsy can confirm whether rejection is occurring and how severe it is, which helps the transplant team decide on the best treatment approach. In some transplant centers, biopsies are performed routinely at scheduled intervals even when there are no symptoms, to catch rejection as early as possible.^[4][10]

Other tests that help in evaluating for rejection include imaging studies such as ultrasound or CT scans, immunologic tests, and a thorough clinical evaluation by the transplant team. These tests provide additional information about how the liver is functioning and whether changes in treatment are needed.^[4]

Treatment in Clinical Trials: New Approaches on the Horizon

While standard immunosuppressive medications have greatly improved outcomes for liver transplant recipients, researchers continue to search for better ways to prevent and treat rejection. Clinical trials are testing new medications, innovative diagnostic tools, and novel treatment strategies that could make rejection easier to manage and reduce the side effects of long-term immunosuppression.

One area of active research involves developing better diagnostic tests that can detect rejection earlier and without the need for a liver biopsy. A new blood-based test called OmniGraf Liver is designed to identify subclinical acute rejection by analyzing gene expression patterns in the blood. This test examines which genes are active in the patient’s blood cells and compares them to patterns seen in people with confirmed rejection. The goal is to catch rejection before it causes damage and to help doctors know whether a patient’s immunosuppressive medications are properly balanced. If validated in further studies, this type of test could reduce the need for invasive biopsies while improving early detection of rejection.^[4][10]

Researchers are also investigating novel immunosuppressive agents that might be more effective or cause fewer side effects than currently available medications. Some experimental drugs work through different mechanisms to suppress the immune system, potentially offering benefits for patients who don’t respond well to standard treatments or who experience significant side effects.

Another promising area of research involves trying to induce immune tolerance, where the recipient’s immune system learns to accept the transplanted liver without needing lifelong immunosuppression. This would be revolutionary because it could eliminate the need for daily medications and their associated side effects and risks. Scientists are exploring various approaches to achieve tolerance, including manipulating certain immune cells before or after transplant, but this remains an area of active investigation rather than standard practice.

Studies are also looking at ways to personalize immunosuppression—tailoring the type and dose of medications to each individual patient based on their specific immune characteristics, genetic makeup, or biomarker profiles. This precision medicine approach could help identify which patients need more or less immunosuppression, reducing both rejection rates and medication side effects.

Clinical trials testing new rejection treatments typically proceed through three phases. Phase I trials focus primarily on safety—researchers want to know whether a new treatment causes unacceptable side effects and what dose range is safe. These trials usually involve small numbers of patients. Phase II trials expand testing to more patients and begin to evaluate whether the treatment actually works—does it prevent or treat rejection effectively? Phase III trials are large studies that compare the new treatment to the current standard treatment to determine whether the new approach is better, equivalent, or not as good. Only treatments that successfully pass through all phases can be approved for general use.

Patients in the United States, Europe, and other regions around the world may have access to clinical trials testing new rejection treatments. Eligibility for trials varies depending on factors such as time since transplant, overall health status, presence or absence of rejection, and other medical conditions. Your transplant center can provide information about available trials and whether you might qualify to participate.

Most Common Treatment Methods

• Immunosuppressive Medications
  • Tacrolimus: A primary immunosuppressant that blocks T-cell activation to prevent the immune system from attacking the new liver
  • Cyclosporine: Another T-cell inhibitor used as an alternative to tacrolimus in some patients
  • Prednisone: A corticosteroid that reduces inflammation and suppresses immune responses
  • These medications must be taken lifelong, with doses adjusted based on blood levels and patient response
• Acute Rejection Treatment
  • High-dose intravenous corticosteroids (steroid boluses): The standard first-line treatment for acute rejection episodes
  • Effective in the majority of cases, with most patients responding well to this therapy
  • Steroid-resistant rejection is uncommon but may require additional immunosuppression adjustments
• Chronic Rejection Management
  • Escalation of immunosuppressive medication doses
  • Changes to different immunosuppressive drugs or combinations
  • May not respond to treatment in some cases, potentially requiring retransplantation
• Supportive Medications
  • Antifungal medications to prevent oral yeast infections
  • Antiviral drugs to prevent herpes and other viral infections
  • Medications to manage side effects such as high blood pressure, diabetes, high cholesterol, and bone loss
• Monitoring and Diagnostic Tools
  • Regular blood tests to check liver function and medication levels
  • Liver biopsies to confirm rejection and assess severity
  • Novel blood-based gene expression tests (such as OmniGraf Liver) being developed to detect subclinical rejection
  • Imaging studies including ultrasound and CT scans

Living Well After Transplant: What Patients Can Do

Recovery from liver transplant surgery and adjusting to life with a new organ typically takes six to twelve months, though this timeframe varies depending on how healthy the patient was before transplant. During this time, regular follow-up visits with the transplant team are essential. In the first two to three months, these appointments may be weekly; later they become less frequent—every few months at first, then usually once a year for life.^[13][17]

Beyond taking medications as prescribed, patients can take several steps to protect their new liver and reduce the risk of rejection. Avoiding infections is crucial because the weakened immune system makes it harder to fight off illnesses. This means practicing good hand hygiene, avoiding crowds during cold and flu season, staying up to date with vaccinations (as recommended by the transplant team), and avoiding contact with people who are sick.^[17]

Maintaining a healthy lifestyle supports both the transplanted liver and overall wellbeing. This includes eating a balanced, nutritious diet; getting regular exercise as approved by the transplant team; avoiding alcohol completely; not smoking; maintaining a healthy weight; and protecting skin from sun exposure to reduce cancer risk. Regular dental care is also important because infections in the mouth can spread to other parts of the body.^[13]

Patients should keep track of their daily activities, medications, test results, and any symptoms they experience. Many transplant centers provide journals or apps to help with this record-keeping. Being an active, informed partner in your healthcare improves outcomes and helps the transplant team provide the best possible care.